Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial

NCT06599216 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT06599216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06599216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 8, 2024
Completion date
September 1, 2027
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hr+/her2- breast cancer